Get the Stockscreener App
13.70
0.54%
-0.075
Sionna Therapeutics Inc stock is traded at $13.70, with a volume of 162.95K.
It is down -0.54% in the last 24 hours and up +0.00% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which Heads to insufficient CFTR function.
See More
Previous Close:
$13.77
Open:
$13.56
24h Volume:
162.95K
Relative Volume:
3.38
Market Cap:
$598.91M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-30.50%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$13.37
$16.12
1-Week Range:
$13.21
$19.93
52-Week Range:
$13.21
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare SION with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
13.71 | 598.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.01 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.63 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
633.30 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.11 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.75 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sionna Therapeutics Inc Stock (SION) Latest News
Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics’ NBD1 stabilizers hold potential for cystic fibrosis - The Pharma Letter
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market - Yahoo Finance
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference - The Manila Times
Can This Clinical-Stage CF Treatment Developer Disrupt a $10B+ Market? Key Presentation Coming - StockTitan
Sionna Therapeutics (SION) Surges in Nasdaq Debut Before Paring Gains - HPBL
Atlas Venture Fund Xi L.P Reports 6.5% Stake In Sionna Therapeutics As Of Feb 10 - Marketscreener.com
The Surprising Stock Insiders Can’t Stop Buying: What’s the Hype? - MotoPaddock
Sionna Therapeutics: The Biotech Stock Insiders Are Snapping Up! - Smartphone Magazine
Sionna Therapeutics: The Under-the-Radar Insider Favorite You’ve Been Missing - Anexartiti
Biopharma Gamble: Why Insiders Are Betting Big on Sionna Therapeutics - DSA
Why Insiders Are Betting Big on Sionna Therapeutics This Year - Bit Perfect Solutions
The Biopharma Gamble: Why Insiders Are Banking on Sionna Therapeutics - Elblog.pl
Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? - Insider Monkey
Sionna therapeutics sees $20.25 million stock purchase by TPG - MSN
Sionna Therapeutics’ $219.2 Million Upsized IPO - Global Legal Chronicle
Major Stock Acquisition Signals Confidence in Sionna Therapeutics - TipRanks
Sionna Therapeutics updates corporate bylaws post-IPO - Investing.com India
Sionna Therapeutics updates corporate bylaws post-IPO By Investing.com - Investing.com Australia
Sionna Therapeutics director Peter Thompson acquires $9.9m in IPO shares - Investing.com India
Major Stakeholders Make Bold Moves on Sionna Therapeutics Stock! - TipRanks
Ra capital management acquires $20.25m in Sionna Therapeutics stock By Investing.com - Investing.com Australia
Ra capital management acquires $20.25m in Sionna Therapeutics stock - Investing.com
Orbimed advisors buys $9.9 million in Sionna Therapeutics stock By Investing.com - Investing.com Nigeria
Orbimed advisors buys $9.9 million in Sionna Therapeutics stock - Investing.com
Sionna Therapeutics, Inc. Completes Upsized IPO Raising Approximately $219.2 Million to Advance Cystic Fibrosis Treatments - Nasdaq
Sionna Therapeutics Announces Closing of $219.2 million - GlobeNewswire
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Benzinga
Cystic Fibrosis Biotech Startup Secures Massive $219M War Chest in Oversubscribed Nasdaq Debut - StockTitan
Share in cystic fibrosis firm Sionna rise sharply after IPO - pharmaphorum
🔬 Latest pharma industry updates 👇 - substack.com
Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline - MedCity News
Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut - Smartkarma
Cystic fibrosis drug developer Sionna rises on trading debut - MSN
Strong demand for Sionna latest good sign for IPOs: Public Equity Report - BioCentury
Sionna IPO Grosses $191m To Compete With Vertex In CF - News & Insights
Opening Day: Sionna Therapeutics, Titan America make public debut - TipRanks
Arrowhead appoints Douglas Ingram as new director - MSN
Sionna Therapeutics prices upsized IPO at $18 per share - MSN
Sionna stock rises on trading debut (SION:NASDAQ) - Seeking Alpha
Cystic fibrosis drug developer raises $191M in first Mass. IPO of 2025 - The Business Journals
Sionna goes public in $135M IPO, Aardvark plots $103M listing - Fierce Biotech
Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome - Smartkarma
Goodwin, Ropes Lead Cystic Fibrosis Co.'s Upsized $191M IPO - Law360
ForexTV | Small Business Resources - ForexTV.com
Vertex challenger Sionna prices $191M IPO - BioPharma Dive
Sionna Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know - Benzinga
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Cystic fibrosis company Sionna seeks $150 million raise in IPO - The Pharma Letter
Major Breakthrough in Cystic Fibrosis Treatment: Sionna Therapeutics Sets Sights on IPO Success - mivalle.net.ar
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
Sionna Therapeutics Inc Stock (SION) Financials Data
There is no financial data for Sionna Therapeutics Inc (SION). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Sionna Therapeutics Inc Stock (SION) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Feb 10 '25 |
Buy |
18.00 |
1,125,000 |
20,250,000 |
6,923,365 |
| ORBIMED ADVISORS LLC | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Thompson Peter A. | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Booth Bruce | Director |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):